title: Effect of neoadjuvant chemotherapy in hepatic steatosis.
abstract: Chemotherapy drugs often produce side effects in the liver. In recent years, there has been speculation about the ability to produce hepatic steatosis in patients treated with 5-fluorouracil and oxaliplatin. This prospective study examines whether these drugs can produce steatosis in patients with neoadjuvant treatment who were operated on for liver tumors.
  
  
  OBJECTIVE
  Our objective was to assess the effect of neoadjuvant chemotherapy (NAC) on the development of hepatic steatosis in the healthy liver.
  
  
  METHODS
  This was a prospective study based on 32 patients divided into two groups. The presence of steatosis was assessed using a histological score (Kleiner classification) and a biochemical method (Folch method) for patients from both groups.
  
  
  RESULTS
  A total of 14 patients (44%) had hepatic steatosis and half of these were in each group. The steatosis was moderate to severe (grades 2-3) in 4 patients (13%), 2 in each group. The mean levels of triglycerides in the liver were 33.38 and 29.94 mg/g in group I and group II, respectively, with the difference not being statistically significant.
  
  
  CONCLUSIONS
  Almost half of the patients treated with NAC for liver neoplasia developed steatosis. Nevertheless, NAC does not seem to increase the risk of hepatic steatosis.
authors.affiliation: Department of Surgery, Donostia Hospital, San Sebastián, Spain.
authors.forename: Raúl
authors.initials: R
authors.lastname: Jiménez
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hijona
authors.forename: José
authors.initials: J
authors.lastname: Emparanza
authors.forename: Jose M
authors.initials: JM
authors.lastname: Alústiza
authors.forename: Lander
authors.initials: L
authors.lastname: Hijona
authors.forename: Maria T
authors.initials: MT
authors.lastname: Macarulla
authors.forename: Maria P
authors.initials: MP
authors.lastname: Portillo
authors.forename: Marta
authors.initials: M
authors.lastname: Herreros-Villanueva
authors.forename: Adolfo
authors.initials: A
authors.lastname: Beguiristain
authors.forename: Juan
authors.initials: J
authors.lastname: Arenas
authors.forename: Luis
authors.initials: L
authors.lastname: Bujanda
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D005234:Fatty Liver / Q000209:etiology / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D011446:Prospective Studies; D014280:Triglycerides / Q000032:analysis
chemical_list: D009944:Organoplatinum Compounds; D014280:Triglycerides; D000077150:Oxaliplatin; D005472:Fluorouracil